What do we know?, page-5

As you seem determined to be pedantic, let’s look at your objections:

1. You objected to my statement that “Yesterday’s announcement said that the first patient had been treated, so we know that there were no serious adverse reactions”. This is surely a true statement – there was no serious reaction when Veyonda was first administered, otherwise the trial would have been halted. Whether serious events occur later in the trial remains to be seen.
2. I wrote that “Having failed prior treatment, any improvement in their WHO score should be attributable to Veyonda”. I did not say that a response must be attributable to Veyonda, but I respectfully suggest that Noxopharm would have done everything within their control in the protocol design to avoid data contamination.

I am certainly not privy to confidential trial data. My objective here is to provide a succinct summary for readers who do not have the time to research Noxopharm.